NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world data.

ABSTRACT:

Background

NALIRIFOX, a triplet chemotherapy regimen combining nanoliposomal irinotecan, 5-fluorouracil/leucovorin, and oxaliplatin, demonstrated superior survival outcomes versus gemcitabine plus nab-paclitaxel in the NAPOLI 3 trial for metastatic pancreatic ductal adenocarcinoma (mPDAC). However, its performance in routine clinical practice remains underexplored.

Patients and methods

This multicenter retrospective study evaluated the real-world efficacy and safety of NALIRIFOX as first-line treatment in 80 patients with mPDAC. Primary endpoints were time to failure of strategy (TFS) and overall survival (OS). Secondary endpoints included treatment-related toxicity, disease control rate (DCR), and molecular subgroup analyses based on homologous recombination repair mutation

SUBMITTER: Reichinger A 

PROVIDER: S-EPMC12523076 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature